Nishita Singh, Mohammed A Almekhlafi, Fouzi Bala, Ayoola Ademola, Shelagh B Coutts, Yan Deschaintre, Houman Khosravani, Brian Buck, Ramana Appireddy, Francois Moreau, Gord Gubitz, Aleksander Tkach, Luciana Catanese, Dar Dowlatshahi, George Medvedev, Jennifer Mandzia, Aleksandra Pikula, Jai Jai Shankar, Esseeddeegg Ghrooda, Alexandre Y Poppe, Heather Williams, Thalia S Field, Alejandro Manosalva, Muzaffar M Siddiqui, Atif Zafar, Oje Imoukhoude, Gary Hunter, Michel Shamy, Andrew M Demchuk, Brian L Claggett, Michael D Hill, Tolulope T Sajobi, Richard H Swartz, Bijoy K Menon
BACKGROUND: The AcT (Alteplase Compared to Tenecteplase) randomized controlled trial showed that tenecteplase is noninferior to alteplase in treating patients with acute ischemic stroke within 4.5 hours of symptom onset. The effect of time to treatment on clinical outcomes with alteplase is well known; however, the nature of this relationship is yet to be described with tenecteplase. We assessed whether the association of time to thrombolysis treatment with clinical outcomes in patients with acute ischemic stroke differs by whether they receive intravenous tenecteplase versus alteplase...
November 2023: Stroke; a Journal of Cerebral Circulation